CTRI/2024/01/061159招募中4 期
A Prospective, Open Label, multi-country, multi-Centre, post marketing surveillance of vivo-Isar in real world patients undergoing percutaneous coronary intervention with short dual-antiplatelet therapy - Nil
试验速览
- 阶段
- 4 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Ability to provide written informed consent.
- •Treated only with the VIVO ISAR stent system.
- •More than 18 years old.
- •Male or non-pregnant female patient.
- •Intended for treatment with = 3 months DAPT after PCI as per standard of care.
排除标准
- •Cardiogenic shock hemodynamic instability around the time of the index procedure.
- •Concurrent medical condition with a life expectancy of less than 12
- •Allergy or contraindication to antiplatelet therapy cobalt chromium
- •sirolimus or any known hypersensitivity to the planned anti-platelet drugs.
- •History of cerebrovascular accident in the last 6 months.
- •Pregnant female.
- •PCI performed within the previous 3 months from the date of index procedure.
研究者
相似试验
进行中（未招募）
1 期
HEP002 is a clinical study designed for paediatric patients with urea cycle disorders (UCD). UCD patients will receive several infusions of HepaStem. The efficacy as well as the safety of the medicinal product will be assessed during the year following infusions.EUCTR2014-000650-11-ESPromethera Biosciences6
招募中
1 期
An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC)Oligometastatic prostate cancer (OMPC)MedDRA version: 21.1Level: PTClassification code: 10071119Term: Hormone-dependent prostate cancer Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10036909Term: Prostate cancer metastatic Class: 100000004864CTIS2022-502956-29-00ovartis Pharma AG430
尚未招募
3 期
PSMA-DC: An Open-label study comparing lutetium (177Lu) vipivotide tetraxetan (also known as [177Lu]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617) versus observation in PSMA positive OMPC.Oligometastatic Prostate Cancer (OMPC) by PSMA PET, M1 negative by CI.JPRN-jRCT2031230608Yamauchi Kyosuke20
进行中（未招募）
不适用
A prospective, open-label, international, multicenter trial to investigate the efficacy and safety of NT 201, free of complexing proteins, in the treatment of glabellar frown lines - NT-SPUTNIKEUCTR2008-000549-73-DEMerz Pharmaceuticals GmbH101
招募中
1 期
An international prospective open-label, multi-center, randomized, non-comparative phase II study of lutetium [177Lu] vipivotide tetraxetan alone and lutetium [177Lu] vipivotide tetraxetan in combination with androgen receptor pathway inhibitors in patients with PSMA PET scan positive castration-resistant prostate cancer (PSMACare)PSMA PET scan positive Castration-Resistant Prostate Cancer (CRPC)MedDRA version: 21.1Level: LLTClassification code: 10076506Term: Castration-resistant prostate cancer Class: 10029104CTIS2022-503040-41-00ovartis Pharma AG120